The New England journal of medicine
-
Letter Retraction Of Publication
Retraction: Steering CAR T Cells into Solid Tumors. N Engl J Med 2019;380:289-91.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. ⋯ Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).